Filing Flows › Beam Therapeutics (BEAM) › Guidance & outlook
Beam Therapeutics (BEAM) guidance and outlook
Beam Therapeutics' 10-Q filed Nov 3, 2026 makes 42 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 3, 2026
- Our suite of gene editing technologies is anchored by our proprietary base editing technology, which potentially enables a differentiated class of precision genetic medicines that target a single base in the genome without making a double-stranded break in the DNA.
- Our proprietary base editors have two principal components: (i) a clustered regularly interspaced short palindromic repeats, or CRISPR, protein, bound to a guide RNA, that leverages the established DNA-targeting ability of CRISPR, but is modified to not cause a double-stranded break, and (ii) a base editing enzyme, such as a deaminase, which carries out the desired chemical modification of the target DNA base.
- Our goal is to advance a broad, diversified portfolio of base editing programs against distinct, genetically validated editing targets, as well as an innovative, platform business model that will expand the reach of our programs to more patients.
- We expect to report updated data for the BEACON clinical trial by year-end 2026, and expect to submit a biologics license application, or BLA, for risto-cel as early as year-end 2026.
- We continue to develop targeted LNPs for the in vivo delivery of gene editing payloads to HSCs.
- We have identified targeted LNPs that have the potential for HSC delivery and are currently engaged in lead optimization.
- Based on feedback from the FDA, we intend to pursue an accelerated approval pathway for BEAM-302 based on a primary endpoint of AAT biomarkers evaluated over 12 months, with 60 mg as the selected dose.
- To support a future BLA submission, we anticipate enrolling approximately 50 additional patients with AATD-associated lung disease, with or without liver disease, in an expansion of the ongoing open-label Phase 1/2 trial.
- Enrollment and dosing of patients in this global pivotal cohort are ongoing and we expect to complete dosing in this pivotal cohort in the first half of 2027.
- Initially, we plan to develop BEAM-304 for the treatment of the two most prevalent variants found in PKU patients in the United States, with ongoing research effort to
- In October 2026, we nominated a third development candidate within the BEAM-304 program, targeting a third undisclosed PKU mutation.
- We are engaged in clinical start-up activities for the planned Phase 1/2 trial of BEAM-304 and we expect to initiate dosing in the Phase 1/2 trial in early 2027.
Beam Therapeutics' latest quarter
Beam Therapeutics, Q3 2026: revenue $307K (-97% year over year), net loss $134M, operating cash flow −$111M. The chart follows the revenue to costs, profit and cash.
Questions
What does Beam Therapeutics expect?
Our suite of gene editing technologies is anchored by our proprietary base editing technology, which potentially enables a differentiated class of precision genetic medicines that target a single base in the genome without making a double-stranded break in the DNA. Our proprietary base editors have two principal components: (i) a clustered regularly interspaced short palindromic repeats, or CRISPR, protein, bound to a guide RNA, that leverages the established DNA-targeting ability of CRISPR, but is modified to not cause a double-stranded break, and (ii) a base editing enzyme, such as a deamina
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.